Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Vivo’s Three Fund Vehicles
Private Equity
Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation. Our private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. We invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.
Public Equity
Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.
Our Team
artrix2023-08-07T23:46:24-07:00
Our Portfolio
News
RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication GalleryRareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication
